Company

TiGenix NV (NYSE Euronext: TIG) is a leading European cell therapy company with an advanced clinical stage pipeline of adult stem cell programmes, and a commercialised product.

The stem cell programmes are based on a validated platform of allogeneic expanded adipose-derived stem cells (eASCs) targeting autoimmune and inflammatory diseases. Built on solid pre-clinical and CMC packages, they are being developed in close consultation with the European Medicines Agency.  CX601 is in Phase III to treat complex perianal fistulas in patients with Crohn’s disease. Cx611 has successfully concluded a Phase IIa trial in rheumatoid arthritis, and is now in development for early rheumatoid arthritis and for severe sepsis.

Effective as of July 31, 2015, TiGenix acquired Coretherapix, whose lead cellular product (AlloCSC-01) is currently in a Phase II clinical trial in acute myocardial infarction (AMI). Coretherapix is planning to initiate the clinical evaluation of AlloCSC-01 in the chronic setting as well and is also involved in the pre-clinical development of a pharmaceutical formulation of growth factors to treat AMI.

The company’s commercialised product, ChondroCelect®, for cartilage repair in the knee, was the first approved cell-based product in Europe, and is marketed and distributed by Swedish Orphan Biovitrum AB (‘Sobi’, NASDAQ OMX Stockholm: SOBI) and Finnish Red Cross Blood Service (FRCBS). TiGenix is based in Leuven, Belgium, and has operations in Madrid , Spain.

Read more...

Products

Pipeline Update

Read more...

Latest News

23 August 2015 - TiGenix announces Cx601 meets primary endpoint in pivotal Phase III trial (EN - NL - FR)

7 August 2015 - TiGenix obtains FDA’s endorsement through Special Protocol Assessment for its Cx601 Phase III registration trial in the US (EN - NL - FR)

7 August 2015 - TiGenix publishes transparency notification pursuant to Article 14 of the Law of May 2, 2007 (EN - NL)

31 July 2015 - Transparency Information (EN - NL)

31 July 2015 - Dirk Büscher and José Terencio resign from TiGenix board of directors (EN - NL - FR)

Read more...

Webcast details

Please dial one of the following numbers to participate:

Belgium: +32 (0) 2404 0662
Canada: +1 514 841 2154
France: +33 (0) 1 76 77 22 26
Netherlands: +31 (0) 20 716 8257
Spain: +34 91 453 3445
Sweden: +46 (0) 8 5065 3936
United Kingdom: +44 (0) 20 3427 1900
United States of America: +1 646 254 3365

Confirmation code: 8585083

The webcast can be followed live online via the link: http://edge.media-server.com/m/p/kvidxhyn

Management presentations

2014 full year results webcast recording, March 2015

Tigenix at Alliance for Regenerative Medicine Conference, March 2015

TiGenix on Kanaal Z television, November 2014

Company factsheet and slide deck

Company factsheet

2015 - Corporate Presentation